Tuesday, September 27, 2011

Avastin Monopoly Challenged - BIBF1120

At ESMO, Boehringer Ingelheim presented early stage data from a head to head study comparing its orally administered triple angiokinase inhibitor BIBF 1120 with Avastin in metastatic colorectal patients. The median PFS was numerically similar in both the arms, but on the safety front, BIBF-1120 is better.  The rate of  serious adverse events in the BIBF-1120 arm was 34% as compared to 54% in the Avastin arm. A large PhIII study is planned.. 

BIBF 1120  targets three of the receptor tyrosine kinases shown to aid in the regulation of angiogenesis, or the formation of blood vessels: fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor

No comments:

Post a Comment